In a report published in the March 3 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report, interim clinical treatment considerations are presented for severe manifestations of mpox. In a report published in the March 3 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report, interim clinical treatment considerations are presented for severe manifestations of mpox. Agam K. Rao, M.D., from the CDC in Atlanta, and colleagues note that most of the patients affected by mpox have been immunocompetent and experienced 10 or fewer rash lesions. Supportive care, including pain control, is recommended for these patients. However, certain patients, especially those with moderate or severe immunocompromise, such as advanced HIV infection, have experienced severe manifestations of mpox, including ocular lesions, neurologic complications, myopericarditis, mucosal lesion complications, and uncontrolled viral spread. Therapeutic medical countermeasures (MCMs) developed for smallpox or shown to be effective against Orthopoxvirus (OPXV) have been used for severe mpox. Source: Advances and More licensed by HealthDay

read more